Check-Cap Ltd. (CHEK) Upgraded to “Buy” by Zacks Investment Research
Check-Cap Ltd. (NASDAQ:CHEK) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Tuesday. The firm presently has a $2.00 target price on the medical research company’s stock. Zacks Investment Research‘s price target points to a potential upside of 6.95% from the company’s current price.
According to Zacks, “Check Cap Ltd. is a medical diagnostics company. The company is engaged in the development of an ingestible imaging capsule for the screening of colorectal cancer. Check Cap Ltd. is based in Mount Carmel, Israel. “
Several other research analysts also recently weighed in on CHEK. HC Wainwright reiterated a “buy” rating and issued a $7.00 price target (up from $6.00) on shares of Check-Cap in a report on Thursday, September 28th. Maxim Group reaffirmed a “buy” rating and issued a $5.00 target price on shares of Check-Cap in a research report on Wednesday, September 27th. Finally, ValuEngine raised Check-Cap from a “strong sell” rating to a “sell” rating in a research note on Thursday, August 17th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $5.00.
Shares of Check-Cap (NASDAQ:CHEK) traded up 1.63% during midday trading on Tuesday, hitting $1.87. 42,330 shares of the company were exchanged. The stock’s market capitalization is $31.75 million. The company has a 50-day moving average price of $1.81 and a 200-day moving average price of $1.81. Check-Cap has a 52-week low of $1.70 and a 52-week high of $2.95.
Check-Cap (NASDAQ:CHEK) last posted its quarterly earnings data on Thursday, August 10th. The medical research company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). On average, analysts forecast that Check-Cap will post ($0.63) EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Check-Cap Ltd. (CHEK) Upgraded to “Buy” by Zacks Investment Research” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/10/03/check-cap-ltd-chek-upgraded-to-buy-by-zacks-investment-research.html.
A hedge fund recently raised its stake in Check-Cap stock. Sabby Management LLC grew its holdings in shares of Check-Cap Ltd. (NASDAQ:CHEK) by 467.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,418,893 shares of the medical research company’s stock after purchasing an additional 1,169,061 shares during the period. Check-Cap accounts for 0.1% of Sabby Management LLC’s portfolio, making the stock its 24th biggest position. Sabby Management LLC owned approximately 8.36% of Check-Cap worth $2,724,000 as of its most recent SEC filing. 19.29% of the stock is owned by hedge funds and other institutional investors.
Check-Cap Ltd. (Check-Cap) is a clinical-stage medical diagnostics company. The Company is engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The Company’s system consists of main components, such as ingestible scanning capsule; Capsule Positioning System (CPS), a recorder worn on the patient’s back, and a personal computer (PC)-based work station for data reconstruction and image processing.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Check-Cap Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check-Cap Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.